Literature DB >> 8020561

Activation of phosphatidylinositol-3-kinase in Jurkat T cells depends on the presence of the p56lck tyrosine kinase.

M von Willebrand1, G Baier, C Couture, P Burn, T Mustelin.   

Abstract

Activation of resting T lymphocytes by ligands to the T cell receptor (TcR)/CD3 complex is initiated by phosphorylation of a number of key regulatory proteins on specific tyrosine residues. One such protein is the heterodimeric enzyme phosphatidylinositol-3-kinase (PI3K). We recently found that this enzyme is also rapidly activated following TcR/CD3 triggering and that immunoprecipitated PI3K was activated in vitro by direct tyrosine phosphorylation. Here we show that TcR/CD3-induced tyrosine phosphorylation and activation of PI3K in Jurkat T leukemia cells depend on the presence of the p56lck tyrosine kinase: in a variant of the Jurkat T cell line lacking p56lck, JCaM1, these responses were absent. We also show that p56lck directly activates PI3K purified from transfected COS-1 cells, indicating that other T cell-specific proteins are not required for the process. Finally, tryptic peptide maps show that p56lck phosphorylates three tyrosine residues in the p85 alpha subunit of PI3K and two in p110 of PI3K. Our results suggest that p56lck is required for activation of PI3K in Jurkat T cells and can itself directly activate it by phosphorylating one or several stimulatory sites.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8020561     DOI: 10.1002/eji.1830240137

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Inhibition of phosphatidylinositol 3-kinase activity by association with 14-3-3 proteins in T cells.

Authors:  N Bonnefoy-Bérard; Y C Liu; M von Willebrand; A Sung; C Elly; T Mustelin; H Yoshida; K Ishizaka; A Altman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

2.  Proline-rich tyrosine kinase 2 controls PI3-kinase activation downstream of the T cell antigen receptor in human T cells.

Authors:  Nicole M Chapman; Ashley N Yoder; Kathryn M Barbón; Mahmood Y Bilal; Sean F Connolly; Jon C D Houtman
Journal:  J Leukoc Biol       Date:  2014-11-11       Impact factor: 4.962

3.  Evidence for an association of CD45 with 32,000-33,000 MW phosphoproteins on murine T and B lymphocytes.

Authors:  J G Altin; E B Pagler; C R Parish
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

4.  Phorbol ester treatment inhibits phosphatidylinositol 3-kinase activation by, and association with, CD28, a T-lymphocyte surface receptor.

Authors:  J E Hutchcroft; D P Franklin; B Tsai; D Harrison-Findik; L Varticovski; B E Bierer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

5.  Src-induced activation of inducible T cell kinase (ITK) requires phosphatidylinositol 3-kinase activity and the Pleckstrin homology domain of inducible T cell kinase.

Authors:  A August; A Sadra; B Dupont; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

6.  Recruitment of SLP-76 to the membrane and glycolipid-enriched membrane microdomains replaces the requirement for linker for activation of T cells in T cell receptor signaling.

Authors:  N J Boerth; J J Sadler; D E Bauer; J L Clements; S M Gheith; G A Koretzky
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

7.  FGF signaling controls caudal hindbrain specification through Ras-ERK1/2 pathway.

Authors:  Ferran Aragon; Cristina Pujades
Journal:  BMC Dev Biol       Date:  2009-12-03       Impact factor: 1.978

8.  CD28 signals through acidic sphingomyelinase.

Authors:  L M Boucher; K Wiegmann; A Fütterer; K Pfeffer; T Machleidt; S Schütze; T W Mak; M Krönke
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

9.  HTLV-1 Tax deregulates autophagy by recruiting autophagic molecules into lipid raft microdomains.

Authors:  T Ren; Y Takahashi; X Liu; T P Loughran; S-C Sun; H-G Wang; H Cheng
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.